Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.

Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guérin A.

Adv Ther. 2017 Jul;34(7):1673-1685. doi: 10.1007/s12325-017-0551-6. Epub 2017 Jun 3.

PMID:
28578501
2.

Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.

Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guérin A.

Adv Ther. 2017 May;34(5):1145-1156. doi: 10.1007/s12325-017-0527-6. Epub 2017 Apr 12.

PMID:
28405961
3.

The economic burden of brain metastasis among lung cancer patients in the United States.

Guérin A, Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Macalalad AR.

J Med Econ. 2016;19(5):526-36. doi: 10.3111/13696998.2016.1138962. Epub 2016 Jan 22.

PMID:
26735844
4.

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer.

Song Y, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, Wu EQ.

Breast Cancer (Auckl). 2015 Sep 3;9:67-72. doi: 10.4137/BCBCR.S30771. eCollection 2015.

5.

Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.

Guérin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP.

JAMA Oncol. 2015 Sep;1(6):797-805. doi: 10.1001/jamaoncol.2015.2407. Erratum in: JAMA Oncol. 2015 Oct;1(7):989.

PMID:
26204106
6.

Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.

Guérin A, Sasane M, Wakelee H, Zhang J, Culver K, Dea K, Nitulescu R, Galebach P, Macalalad AR.

Curr Med Res Opin. 2015 Aug;31(8):1587-97. doi: 10.1185/03007995.2015.1057115. Epub 2015 Jun 29.

PMID:
26029864
7.

ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.

Guérin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H.

Cancer Epidemiol. 2015 Jun;39(3):307-12. doi: 10.1016/j.canep.2015.04.005. Epub 2015 Apr 23.

PMID:
25914136
8.

The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.

Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V.

Curr Med Res Opin. 2015 Mar;31(3):537-45. doi: 10.1185/03007995.2015.1008131. Epub 2015 Feb 9. Review.

PMID:
25598441
9.

Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).

Macalalad AR, Hao Y, Lin PL, Signorovitch JE, Wu EQ, Ohashi E, Zhou Z, Kelley C.

Curr Med Res Opin. 2015 Feb;31(2):263-73. doi: 10.1185/03007995.2014.980885. Epub 2014 Nov 7.

PMID:
25350226
10.

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.

Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ.

Curr Med Res Opin. 2013 Sep;29(9):1075-82. doi: 10.1185/03007995.2013.812034. Epub 2013 Jun 21.

PMID:
23738923
11.

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.

Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ.

Curr Med Res Opin. 2013 Jun;29(6):623-31. doi: 10.1185/03007995.2013.789012. Epub 2013 Apr 8.

PMID:
23517347
12.

Highly sensitive and specific detection of rare variants in mixed viral populations from massively parallel sequence data.

Macalalad AR, Zody MC, Charlebois P, Lennon NJ, Newman RM, Malboeuf CM, Ryan EM, Boutwell CL, Power KA, Brackney DE, Pesko KN, Levin JZ, Ebel GD, Allen TM, Birren BW, Henn MR.

PLoS Comput Biol. 2012;8(3):e1002417. doi: 10.1371/journal.pcbi.1002417. Epub 2012 Mar 15.

13.

Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection.

Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S, Zody MC, Erlich RL, Green LM, Berical A, Wang Y, Casali M, Streeck H, Bloom AK, Dudek T, Tully D, Newman R, Axten KL, Gladden AD, Battis L, Kemper M, Zeng Q, Shea TP, Gujja S, Zedlack C, Gasser O, Brander C, Hess C, Günthard HF, Brumme ZL, Brumme CJ, Bazner S, Rychert J, Tinsley JP, Mayer KH, Rosenberg E, Pereyra F, Levin JZ, Young SK, Jessen H, Altfeld M, Birren BW, Walker BD, Allen TM.

PLoS Pathog. 2012;8(3):e1002529. doi: 10.1371/journal.ppat.1002529. Epub 2012 Mar 8.

14.

Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity.

OhAinle M, Balmaseda A, Macalalad AR, Tellez Y, Zody MC, Saborío S, Nuñez A, Lennon NJ, Birren BW, Gordon A, Henn MR, Harris E.

Sci Transl Med. 2011 Dec 21;3(114):114ra128. doi: 10.1126/scitranslmed.3003084.

15.

GB virus C and mortality from HIV infection.

Macalalad AR, Snydman DR.

N Engl J Med. 2002 Jan 31;346(5):377-9. No abstract available.

PMID:
11824420

Supplemental Content

Loading ...
Support Center